"Let's say in drug discovery, if we licensed our technology, you have a breakthrough. The drug takes off, and we get a licensed portion of all its sales,"
"It's great alignment for us with our customer,"
"Ads plus AI is sort of uniquely unsettling to me,"
"I kind of think of ads as a last resort for us for a business model."
OpenAI is exploring licensing models that would let the company take a share of downstream sales when a customer product succeeds. Such revenue-sharing could apply in sectors like drug discovery, where OpenAI would receive a portion of sales if licensed technology produces a breakthrough. OpenAI has expanded beyond a single ChatGPT subscription into multiple pricing tiers, enterprise SaaS pricing, and credit-based options. The company plans to test ads in ChatGPT to help cover rapidly rising compute costs while maintaining an ad-free tier. OpenAI faces large future spending commitments, and advertising had previously been characterized as a last-resort option.
Read at Business Insider
Unable to calculate read time
Collection
[
|
...
]